亞盛醫藥-B(06855.HK)與美國國家癌症研究所達成合作 推進Bcl-2/Bcl-xL抑制劑APG-1252臨牀開發
格隆匯7月19日丨亞盛醫藥-B(06855.HK)發佈公吿,公司與美國國立衞生研究院下屬的美國國家癌症研究所(NCI)達成合作研發協議(CRADA),雙方將針對亞盛醫藥原創雙靶點Bcl-2/Bcl-xL抑制劑APG-1252(Pelcitoclax)展開臨牀與非臨牀開發方面的合作。
根據CRADA的條款,亞盛醫藥將與NCI合作展開一系列臨牀試驗,基於亞盛醫藥以往試驗中觀察到的APG-1252抗腫瘤活性,評估該品種在實體瘤治療中的安全性和有效性。NCI還將開展一系列非臨牀相關研究,重點探索APG-1252的生物活性以及與其他靶向藥物的聯合應用。隨着雙方贊助的相關試驗研究數據的生成,亞盛醫藥和NCI將開展更多的試驗來支持APG-1252的臨牀開發。
據悉,APG-1252(Pelcitoclax)為亞盛醫藥自主研發的新型Bcl-2/Bcl-xL雙靶點抑制劑,採用前藥設計來提高其治療指數、降低細胞通透性和血小板毒性。APG-1252對Bcl-2和Bcl-xL具有高度結合親和力,在臨牀前模型中展現出顯着抗白血病活性。
APG-1252正在開展一項多中心、開放性的I期計量遞增試驗,評估其在轉移性小細胞肺癌(SCLC)或其他實體瘤中的安全性、藥物動力學和初步抗腫瘤活性。為克服治療產生的耐藥性,APG-1252聯合其他療法也是一種潛在可行的臨牀方案。目前,APG-1252聯合紫杉醇治療復發╱難治SCLC的臨牀試驗正在進行中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.